Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program

Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program

Histone modifications in cancer can contribute to pathogenesis. Here, the authors demonstrate that targeting epigenetic modifier Ezh2 hinders metastatic behaviour in Luminal B breast cancer models, and highlight a mechanism where Ezh2 contributes to metastatic behaviour by repression of FOXC1.

Bibliographic Details
Main Authors: Alison Hirukawa, Harvey W. Smith, Dongmei Zuo, Catherine R. Dufour, Paul Savage, Nicholas Bertos, Radia M. Johnson, Tung Bui, Guillaume Bourque, Mark Basik, Vincent Giguère, Morag Park, William J. Muller
Format: Article
Language:English
Published: Nature Portfolio 2018-06-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-018-04864-8

Internet

https://doi.org/10.1038/s41467-018-04864-8

Similar Items